- Conditions
- Congestive Heart Failure, Cardiomyopathy
- Interventions
- B-type Natriuretic Peptide (BNP), Placebo
- Drug · Other
- Lead sponsor
- Horng Chen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 2,823
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atopic Dermatitis, Psoriasis
- Interventions
- YR001 Dose A on low body surface area, YR001 Dose A on middle body surface area, YR001 Dose A on high body surface area, YR001 Dose B on low body surface area, YR001 Dose B on middle body surface area, YR001 Dose B on high body surface area, Placebo on low body surface area, Placebo on middle body surface area, Placebo on high body surface area, YR001 Dose A on high body surface area twice daily, YR001 Dose B on high body surface area twice daily, Placebo on high body surface area twice daily
- Drug
- Lead sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Encinitas, California
- Conditions
- Alzheimer's Disease, Central Nervous System Diseases, Cognition
- Interventions
- EVP-6124, Placebo
- Drug
- Lead sponsor
- FORUM Pharmaceuticals Inc
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Chino, California • Costa Mesa, California + 21 more
- Conditions
- Healthy
- Interventions
- cangrelor, moxifloxacin, placebo
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Cystic Fibrosis
- Interventions
- Ivacaftor, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Oakland, California + 30 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl), Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Walnut Creek, California • Saint Paul, Minnesota • Renton, Washington
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- ianalumab, placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 15
- States / cities
- Anniston, Alabama • La Palma, California • Los Angeles, California + 12 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Deutivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 12
- States / cities
- Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Glycopyrrolate (85 μg), Glycopyrrolate (42.5 μg), Glycopyrrolate (14 μg), Placebo
- Drug
- Lead sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 7
- States / cities
- Clearwater, Florida • Tampa, Florida • Saint Charles, Missouri + 4 more
- Conditions
- Alopecia Areata
- Interventions
- PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2, PF-06651600 Maintenance Dose #3, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 718 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Irvine, California + 25 more
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Everolimus, Everolimus Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 742 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 34
- States / cities
- Chandler, Arizona • Fayetteville, Arkansas • La Jolla, California + 29 more
- Conditions
- Iron Deficiency
- Interventions
- Quadruple sequential Helicobacter pylori eradication + iron sulfate, Quadruple sequential Helicobacter pylori eradication therapy, Ferrous sulfate, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 36 Months to 120 Months
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- El Paso, Texas
- Conditions
- Gastroenteritis Escherichia Coli, Immunisation
- Interventions
- Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
- Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy Volunteers
- Interventions
- OLT1177 Gel, Placebo gel
- Drug
- Lead sponsor
- Olatec Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- College Station, Texas
- Conditions
- Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus
- Interventions
- Cebranopadol 100 µg, Cebranopadol 300 µg, Cebranopadol 600 µg, Pregabalin, Matching Placebo
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 699 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 15
- States / cities
- Mesa, Arizona • Garden Grove, California • Laguna Hills, California + 11 more
- Conditions
- Immune Surveillance
- Interventions
- Agaricus blazei, Reishi, Turkey Tail, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Natural Immune Systems Inc
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Klamath Falls, Oregon
- Conditions
- Hyperhidrosis
- Interventions
- Botulinum Type B, Placebo
- Drug
- Lead sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- 75 mg LX4211, 200 mg LX4211, 400 mg LX4211, Placebo
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 56
- States / cities
- Anaheim, California • Carmichael, California • Greenbrae, California + 48 more
- Conditions
- Atopic Dermatitis
- Interventions
- Rocatinlimab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 769 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 44 more
- Conditions
- Lymphoma
- Interventions
- autologous immunoglobulin idiotype-KLH conjugate vaccine, cyclophosphamide, doxorubicin hydrochloride, prednisone, rituximab, sargramostim, vincristine, Intervention/procedure, antibody therapy, biological therapy, chemotherapy, colony-stimulating factor therapy, cytokine therapy, monoclonal antibody therapy, non-specific immune-modulator therapy, therapeutic procedure, tumor cell derivative vaccine, vaccine therapy
- Drug · Procedure
- Lead sponsor
- Favrille
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 2
- States / cities
- Beverly Hills, California • Chapel Hill, North Carolina
- Conditions
- Melanoma
- Interventions
- Fianlimab, Cemiplimab, Pembrolizumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,546 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 5
- States / cities
- La Jolla, California • Los Angeles, California • Orlando, Florida + 2 more
- Conditions
- Healthy Volunteers
- Interventions
- FTX-101, Placebo
- Drug
- Lead sponsor
- Find Therapeutics
- Industry
- Eligibility
- 18 Years to 59 Years · Male only
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Psoriasis
- Interventions
- Daclizumab, NB-UVB
- Drug · Device
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2008
- U.S. locations
- 3
- States / cities
- New York, New York
- Conditions
- Overweight and Obesity
- Interventions
- WVE-007
- Drug
- Lead sponsor
- Wave Life Sciences USA, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Baltimore, Maryland